
Abstract Fetal surgery and therapy have moved from experimental interventions performed in a handful of pioneering centers to established options for selected fetal conditions, and the number of units offering them continues to grow. Training must therefore deliver procedural proficiency, sound case selection, multidisciplinary coordination and patient safety, yet it still depends heavily on the case volume, mentorship and resources of the individual center. This narrative review examines how practitioners in fetal therapy are currently trained and what evidence supports the methods used. We searched the published literature, society consensus statements and program descriptions, appraised the retrieved sources by study design and strength of outcomes, and extracted the quantitative results each reported. Entry to the field is typically through maternal-fetal medicine, obstetrics and gynecology, pediatric surgery or a related discipline; dedicated fellowships exist in selected centers, but there is no international accreditation and no agreed competency benchmark. The quantitative data that exist are consistent in direction and are summarized in three evidence tables: competence signals appear after 20 to 60 fetoscopic laser procedures and after 35 open or at least 56 fetoscopic spina bifida closures, while 48% of centers in a worldwide survey perform fewer than 20 laser procedures annually. Within fetal therapy itself the evidence does not extend beyond single-center simulator validation and clinical learning-curve analysis: no study demonstrates transfer of an educational intervention to patient outcomes, no cost analysis exists for any fetal therapy simulator, and structured assessment of communication and teamwork is largely absent. We set out the unresolved questions and propose conceptual models for curriculum architecture, entrustment and implementation; these have not been prospectively validated and are presented as hypotheses together with the studies required to test them.
Objective To evaluate obstetric and neonatal outcomes among nulliparous patients undergoing induction of labor (IOL) for different clinical indications. Methods This retrospective cohort study included singleton nulliparas at >= 37 weeks' gestation with intact membranes and an unfavorable cervix who underwent IOL at a single academic center over seven years. Participants were categorized by indication: (1) placental complications (hypertensive disorders, fetal growth restriction, abruption, oligohydramnios), (2) diabetes mellitus (DM), (3) isolated fetal macrosomia, (4) prolonged pregnancy (>= 41 weeks), (5) reduced fetal movements (RFM), (6) non-reassuring fetal heart rate (NRFHR), (7) multiple indications (>= 2 of the above), and (8) elective IOL (control). Outcomes were compared between each group and the control. Multivariable logistic regression was performed, with Holm-Bonferroni adjustment for multiple comparisons. Results Among 2582 IOLs, 489 were elective, 447 for placental complications, 194 for DM, 54 for isolated macrosomia, 790 for prolonged pregnancy, 98 for RFM, 97 for NRFHR, and 413 for multiple indications. Isolated macrosomia was associated with higher total CD rates and CD due to labor arrest. NRFHR at presentation was associated with subsequent CD and intervention due to NRFHR, while placental-related and multiple-indication IOLs were associated with intervention due to NRFHR. DM and multiple-indication IOLs were associated with the composite neonatal adverse outcome. In multivariable analyses, isolated macrosomia remained strongly associated with CD due to labor arrest (aOR 5.18, 95% CI 2.65-10.11; Holm-adjusted p < 0.007), while DM and multiple indications were associated with the composite neonatal outcome (aOR 2.06 and 1.81, respectively). Conclusion Among nulliparous patients undergoing IOL, obstetric and neonatal outcomes differed according to the indication for induction. These findings provide indication-specific prognostic information for counseling and intrapartum preparedness but should not be interpreted as comparing the safety of IOL with expectant management.
Introduction Hyperemesis gravidarum has been associated with adverse offspring neurodevelopment, yet its effects on specific fetal brain structures remain poorly understood. This study assessed fetal limbic (fornix-hippocampus complex length and hippocampal thickness) and cortical (gyral-sulcal maturation and subarachnoid space width) development in moderate-to-severe hyperemesis gravidarum using targeted neurosonography. Patients and Methods This prospective cross-sectional study included 33 women hospitalized for moderate-to-severe hyperemesis gravidarum in the first trimester and 44 frequency-matched healthy controls, followed prospectively to third-trimester assessment. Disease severity was graded at admission by the Pregnancy-Unique Quantification of Emesis score, and neurosonography was performed at 28-29 weeks. Hippocampal thickness and fornix-hippocampus length were predefined co-primary outcomes; subarachnoid space width, qualitative gyral-sulcal maturation, and estimated fetal weight were secondary. Severity markers were correlated with neurosonographic measurements within the hyperemesis gravidarum group. Results Hippocampal thickness was significantly lower in the hyperemesis gravidarum group and remained significant after adjustment for confounders (p < 0.001). Fornix-hippocampus length was shorter in the hyperemesis gravidarum group but not significant after adjustment (p = 0.105). Gyral-sulcal maturation was appropriate for gestational age, subarachnoid space width did not differ, and estimated fetal weight was comparable (p > 0.05). Within the hyperemesis gravidarum group, higher Pregnancy-Unique Quantification of Emesis scores, greater weight loss, and longer hospitalization were associated with reduced hippocampal thickness and shorter fornix-hippocampus length (p < 0.05). Conclusions Moderate-to-severe hyperemesis gravidarum was associated with reduced fetal hippocampal thickness, whereas gyral-sulcal maturation, subarachnoid space width, and general fetal growth were comparable between groups, suggesting a possible structure-specific association involving the fetal limbic system.
Introduction Cervical cancer is the fourth most prevalent malignancy among women worldwide, with more patients treated in specialized centers. The WiZen study examines whether treatment at German Cancer Society-certified centers improves survival. Material and Methods This cohort study uses data from eleven statutory health insurance funds (SHI) and four population-based clinical cancer registries (CCRs) in Germany. The analysis includes 10596 incident cervical cancer cases from the AOK dataset and 3468 patients from the CCR dataset who received initial treatment for cervical cancer (ICD-10-GM code C53) between 2009 and 2017. Survival was compared between patients treated at certified centers and non-certified units, using Kaplan-Meier estimators and multivariable Cox models with adjustment for patient and hospital characteristics. Results Based on SHI data, the 5-year overall survival rate estimated by the Kaplan-Meier method was 59.1% for patients treated at certified centers, compared to 53.3% for those at non-certified hospitals. According to CCR data, the corresponding survival rates were 61.6% and 53.2%, respectively. In both cases the survival benefit was highly significant (Log rank p < 0.001). Multivariable hazard ratios (HRs) for mortality favored treatment in certified centers, with an HR of 0.839 (SHI data; 95% confidence interval [CI]: 0.757-0.930; p = 0.001) and 0.741 (CCR data; 95% CI: 0.634-0.865; p < 0.001). Conclusion The findings of this analysis indicate that initial treatment in certified gynecologic cancer centers is associated with a significant survival advantage and should be further promoted as a component of high-quality oncologic care.